This contract expires in 84 days (Sep 30, 2026).
BRISTOL-MYERS SQUIBB COMPANY - MAVACAMTEN (CAMZYOS) AND POMALIDOMIDE (POLMALYST)
Key Details
Description
MAVACAMTEN (CAMZYOS) AND POMALIDOMIDE (POLMALYST)
Context & Analysis
On Feb 11, 2026, Department of Veterans Affairs obligated $356,543.2 to BRISTOL-MYERS SQUIBB COMPANY for mavacamten (camzyos) and pomalidomide (polmalyst). The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition. Performance is located in MEMPHIS, TN. The contract is scheduled through Sep 30, 2026 — approximately 3 months remaining. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.